Balashikha

Researchers are conducting a multi-center, non-interventional study to observe routine diagnostic and treatment practices for patients with unresectable or inoperable locally advanced non-small cell lung cancer (NSCLC) and limited-stage small cell lung cancer (LS-SCLC) in 50 major oncology centers across Russia. The study will collect data from 2000 patients receiving chemo-radiation therapy (CRT) over two years. The aim is to understand demographic and clinical characteristics, diagnostic procedures, treatment approaches, and short-term outcomes of CRT in these patients, without collecting information on treatments following CRT such as durvalumab. The study involves collecting data at two main points: at the start of CRT (either concurrent or sequential chemo-radiation) and after the last dose of radiation therapy, including results from computed tomography (CT) scans. Data collection will be done from patients' medical records in routine clinical practice, and the second data collection is expected to occur within six months after the first visit. The study follows local regulations for adverse event reporting and does not involve additional interventions or treatments. Participants will be adults aged 18 years or older who have locally advanced NSCLC or LS-SCLC and are currently undergoing radiation therapy as part of CRT. Researchers will gather information on patient demographics, disease stage, histology, and clinical status at baseline. The study will monitor treatment details and short-term outcomes after CRT. All data is collected from existing medical records, ensuring no extra procedures for participants. The total participation duration aligns with routine treatment schedules and follow-up visits.

Researchers are evaluating whether adding repeated cisplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC) to standard paclitaxel and carboplatin (TC) chemotherapy improves outcomes in women aged 18 to 75 years with advanced epithelial ovarian cancer and visible peritoneal carcinomatosis. This randomized phase II trial aims to see if repeated PIPAC increases the rate of complete surgical removal of tumors and improves disease control, survival, and safety compared to the standard treatment that includes only one PIPAC procedure. The study focuses on patients with FIGO stage IIIB-IIIC ovarian cancer with peritoneal spread. Participants are randomly assigned during surgery to receive either repeated PIPAC procedures integrated with systemic TC chemotherapy or a single PIPAC during interval cytoreductive surgery, which occurs about 9 to 12 weeks after randomization. PIPAC is administered laparoscopically under general anesthesia using cisplatin delivered as a pressurized aerosol into the abdomen. Treatment includes induction chemotherapy, PIPAC procedures, interval cytoreductive surgery, and postoperative therapies as needed, with detailed surgical and drug delivery protocols. Throughout the trial, participants undergo clinical exams, imaging, laboratory tests, biopsies, and tumor marker monitoring to assess treatment response and safety. Researchers measure the rate of complete tumor removal during surgery as the main outcome. Follow-up includes regular health checks and quality-of-life assessments. Safety monitoring involves tracking adverse events and ensuring precautions during aerosol chemotherapy to protect staff. Participants are followed through treatment and post-therapy surveillance according to the study plan.